Serological responses to rotavirus NSP2 following administration of RV3-BB human neonatal rotavirus vaccine
Daniel Cowley, Daniel Pavlic, Nada Bogdanovic-Sakran, Karen Boniface, Carl D Kirkwood, Julie E Bines
HUMAN VACCINES & IMMUNOTHERAPEUTICS | TAYLOR & FRANCIS INC | Published : 2018
Serum rotavirus IgA responses are an imperfect non-mechanistic correlate of protection, and the lack of an accurate serological marker is a challenge to the development of new rotavirus vaccines. Serological responses to rotavirus NSP2 occur following wild-type infection; however, it is unknown if serological responses to NSP2 occur following administration of rotavirus vaccines. The phase IIa immunogenicity trial of RV3-BB provided an opportunity to investigate the serological responses to NSP2 following vaccination. Healthy, full-term babies (n = 96) were previously recruited as part of a phase IIa safety and immunogenicity trial in Dunedin, New Zealand between January 2012 and April 2014...View full abstract
Awarded by Bill and Melinda Gates Foundation
Awarded by Australian National Health and Medical Research Council
Awarded by New Zealand Health Research Council International Investment Opportunities Fund Trans- Tasman Clinical Trials Collaborative Initiative
This study was funded by an investigator driven grant from the Bill and Melinda Gates Foundation (OPP1127967). The Phase IIa clinical trial of RV3-BB was supported by the Australian National Health and Medical Research Council through a project grant (ID491239) and the New Zealand Health Research Council International Investment Opportunities Fund Trans- Tasman Clinical Trials Collaborative Initiative (08_T02). This research was also supported by the Victorian Government's Operational Infrastructure Support Program.